Rethinking Lifelong Prescriptions

Why Medicine Won’t Cure You—and How That’s Finally Changing

The predatory business model that requires lifelong patients faces its first federal challenge with Kennedy’s historic SSRI initiative

Story at a Glance:

No industry, organization, or cause tasked with solving a problem will actually solve it, because the problem disappearing threatens their economic livelihood or political power.

The pharmaceutical industry has perfected this model: drugs are designed to be taken perpetually rather than cure, side effects create demand for additional drugs, and the entire regulatory apparatus is structured to suppress affordable natural therapies that challenge it.

SSRIs epitomize this dynamic—massively overprescribed, frequently life-ruining, and nearly impossible to withdraw from—yet for decades, the industry successfully kept all criticism of them out of mainstream discourse.

Kennedy announced a multiagency federal effort to combat inappropriate SSRI prescribing, train providers in how to correctly taper patients off antidepressants, and provide non-pharmaceutical alternatives.

•This marks the first time in memory a federal health initiative has aimed to help get patients off a major drug class rather than on one.

When I was in high school, I observed a few discouraging events which led me to postulate: “no industry, organization or cause tasked with solving a problem will actually solve it because the problem disappearing threatens their economic livelihood or political power.” Since that time, I have observed more examples than I can count in so many different spheres that I’ve accepted this dynamic is a common feature of society, and likewise, have come across many similar observations by others, my favorite of which was:

Nothing is so permanent as a temporary government program—Milton Friedman

Recently a noteworthy exampls of this principle came to my attention after I learned all of the online dating apps had switched from formats which allowed people to find suitable long term partners to ones which prevented people from matching, because if someone found a good match, they would stop paying for the service. Once one company figured this out, they bought out all competitors and shifted them to this predatory model as well (and all the profound consequences it entails).1,2,3,4,5,6

Note: because online dating has now become so bad, the companies that monopolized the market are starting to lose a lot of users and money, signaling there may be a chance for this cycle to reset itself.1

This article will focus on how that principle applies to medicine and why I believe beyond greed, complacency also plays a central role in the continual recurrence of this dynamic across societies.

The Forgotten Side of Medicine is a reader-supported publication. To receive new posts and support my work, consider becoming a free or paid subscriber. To see how others have benefitted from this newsletter, click here!

Is Money The Root Of All Evil?

The love of money has long been recognized as one of the most powerful forces for twisting human hearts towards evil. However, I would argue the core issue is that for many people effectively, accumulating money becomes the foundational axiom used to navigate life, causing them to rationalize a variety of unethical positions because their internal algorithm will frequently default to the choice that acquires more money. Recognizing this provides an invaluable tool for understanding the world, as the motivations of others often become far clearer once you view things strictly through what and how they stand to profit from their actions.

Algorithms of Business

In the same way that a default behavior to seek the most profitable choice helps to explain individual actions, businesses also follow a relatively predictable set of behaviors aimed at optimizing profit. In general, most large businesses aim for the following, prioritizing whichever are most feasible:
  • Continual growth
  • High markups on their product
  • The widest possible market
  • Market exclusivity (to protect and maximize sales)
  • Repeating sales far into the future

The pharmaceutical industry excels in all of these, which helps to explain why they have managed to sustain steady growth for decades, and why one-fifth of all money spent in the United States goes to healthcare despite our country receiving very poor returns on that investment.

Note: annual adult vaccines (which frequently do nothing, particularly because they are often for the wrong strain) are an excellent example of an unsafe, unproven and ineffective product that is pushed on everyone because it fulfills the need for perpetually recurring sales.

Lifelong Patients

from:    https://www.midwesterndoctor.com/p/why-medicine-wont-cure-youand-how?publication_id=748806&post_id=211111514&isFreemail=true&r=19iztd&triedRedirect=true&utm_source=substack&utm_medium=email

The Trouble with mRNA FLu Shots

FDA Approves Moderna’s First-Ever mRNA Flu Shot Despite 75.3% Adverse Reaction Rate

The FDA has approved Moderna’s mFLUSIVA for adults 50 and older, making it the first seasonal mRNA influenza injection authorized in the United States.75.3% of senior mRNA-vaccine recipients experienced at least one adverse reaction within seven days, compared with 49.3% of those receiving Fluzone High-Dose.

Even more concerning, severe systemic reactions occurred in 6.7% of mRNA recipients versus 1.7% with the traditional high-dose flu vaccine—nearly four times as frequently.

.

In a dark day for MAHA, the FDA has approved Moderna’s mFLUSIVA for adults 50 and older, making it the first seasonal mRNA influenza injection authorized in the United States. Adults ages 50–64 received traditional approval, while adults 65 and older received accelerated approval based largely on antibody responses.

The FDA’s own briefing document reveals that 75.3% of senior mRNA-vaccine recipients experienced at least one solicited adverse reaction within seven days, compared with 49.3% of those receiving Fluzone High-Dose.

Even more concerning, severe (Grade 3) systemic reactions occurred in 6.7% of mRNA recipients versus 1.7% with the traditional high-dose flu vaccine—nearly four times as frequently.

Even worse, the pivotal efficacy trial contained no placebo group. Instead, Moderna compared mFLUSIVA against traditional flu vaccines.

A novel mRNA injection produced adverse reactions in three out of four recipients, induced severe systemic reactions nearly four times as often as the traditional high-dose vaccine, lacked a placebo-controlled pivotal efficacy trial, and the FDA approved it anyway.

Our regulatory agencies remain CAPTURED.

From:    https://needtoknow.news/2026/08/fda-approves-modernas-first-ever-mrna-flu-shot-despite-75-3-adverse-reaction-rate/?utm_source=aweber&utm_medium=email&utm_campaign=need-to-know-g-edward-griffin-s-news-analysis-2026-aug-13

Missed Your Jabs? Here Is Another Chance.

CDC Awards Pfizer $1.24 Billion for Updated Covid Vaccines

Andrei Vaslilev/iStock/Getty Images Plus

CDC Awards Pfizer $1.24 Billion for Updated Covid Vaccines

For many in the MAHA movement, it is another blow. They hoped President Donald Trump and Robert F. Kennedy Jr.’s Health and Human Services Department (HHS) would confront the devastating carnage of Covid vaccine policy.

Instead, the federal government has just awarded Pfizer new Covid vaccine contracts worth about $1.24 billion.

The contracts cover pediatric and adult doses for fiscal years 2026 and 2027. According to federal procurement records, the pediatric contract carries a ceiling of $735,720,598. The adult contract is valued at about $505.3 million.

The awards come as the Food and Drug Administration (FDA) continues to approve updated boosters, while the Centers for Disease Control and Prevention (CDC) has shifted to a vague “individual-based decision-making” standard for many Americans, without anything close to full informed consent. They also come even though public demand has collapsed for shots associated with some of the gravest harms such as cancer, myocarditis and premature death.

Including these two Covid vaccine contracts, public listings show the Trump administration has awarded the infamous corporation about $7.34 billion in federal contract capacity since March 23, 2025.

Low Demand

The CDC awarded the contracts through its Office of Acquisition Services. The hefty size of these awards raises the most basic procurement question: Who is this product for?

CDC’s own numbers show a market the public has largely abandoned.

As of May 9, 2026, only 9.7 percent of children had been reported as being up to date with the 2025-2026 Covid vaccine. Only 3.0 percent of children had a parent who said they definitely planned to get the child vaccinated.

The adult numbers are not much better.

Even older Americans, the group federal officials say receives the greatest “benefit” from the shots, are not rushing to take them. As of March 28, only 22.6 percent of Medicare fee-for-service beneficiaries 65 and older had been vaccinated.

The same pattern holds among pregnant women, another group federal officials routinely classify as “at risk.” As of May 9, only 11.1 percent of pregnant women had gotten the booster. Put differently, nearly nine in ten expectant mothers — thankfully! — have declined it.

The agency’s commercial claims data also showed about 20.82 million adult doses administered in retail pharmacies, and about 2.47 million in physicians’ offices, as of April 25.

At CDC’s listed Pfizer prices, the $1.24 billion award would cover roughly 13.6 million to 18 million doses. That figure does not prove the government expects demand to rebound. It proves something more revealing. Even after the public walked away, Washington is still underwriting a large Pfizer Covid vaccine market.

It did the same last season. CDC’s archived 2024-2025 vaccine price list shows separate Pfizer contract vehicles for adult and pediatric Covid vaccines, with adult Comirnaty listed at $69.44 per dose and pediatric Pfizer formulas priced between $48.88 and $99.71 per dose. The 2026-2027 awards do not break from that model, they extend it.

The Pediatric Question

The pediatric award is the most explosive part.

Brian Hooker, chief scientific officer at Children’s Health Defense (CHD), a nonprofit founded by Kennedy, put the objection bluntly. He called it “$1.24 billion for what is essentially a cold in minor children.”

At the same time, the risks are enormous. Federal regulators have long known that mRNA Covid vaccines carry an elevated risk of myocarditis and pericarditis, especially in young males. The FDA added myocarditis and pericarditis warnings to Pfizer and Moderna vaccine fact sheets in June 2021. In 2025, the agency required another labeling update, saying the observed risk was highest in males ages 12 through 24. Notably, one recent major study found myocarditis and pericarditis only among vaccinated children, with zero cases recorded among the unvaccinated.

Nor is Washington’s approach universal. For example, early on into the rollout, several Nordic countries moved away from broad Covid vaccination for healthy children and young people.

Florida broke with the policy as well. In 2022, it became the first state to recommend against Covid mRNA vaccination for healthy children. In 2024, the state went further and advised against mRNA Covid vaccines for all populations.

This magazine has extensively documented links between mRNA shots and a range of serious, often irreversible side effects. Those include neurological and immunological damage, menstrual and other reproductive abnormalities, cancer, and premature death. Federal health agencies dispute broad causal claims in those categories. But to this day, they have not produced the kind of transparent, public accounting that would settle the issue for families who were harmed.

Obviously, the new Pfizer contracts do not answer those questions. They simply move past them.

The ACIP Problem

There are also legal and procedural questions.

The CDC’s Advisory Committee on Immunization Practices (ACIP) plays a central role in vaccine recommendations. Its decisions affect federal programs, insurance coverage, and the Vaccines for Children (VCP) program.

Kennedy moved to reshape ACIP. However, a federal judge later blocked many of his appointments and stayed the votes taken by the reconstituted panel, finding that Kennedy’s overhaul likely violated federal law.

That dispute now hangs over federal vaccine policy.

Dr. Robert Malone questioned whether the CDC can properly use vaccine program funds for these purchases without valid ACIP authorization.

“Use of VFC funds requires ACIP authorization,” Malone told CHD. “But there is no ACIP.”

That claim will likely face pushback. Federal agencies often argue that existing schedules, prior recommendations, and procurement authority allow them to maintain supply.

Still, the question is not trivial. If ACIP is frozen, compromised, or legally disputed, then the public deserves clarity before another billion dollars flow to Pfizer.

The Emergency That Never Ends

The contracts also sit beside a larger shield.

The federal Covid public health emergency ended in 2023. But the liability regime under the Public Readiness and Emergency Preparedness Act, known as the PREP Act, did not end with it.

In December 2024, then-outgoing HHS Secretary Xavier Becerra extended the Covid PREP Act declaration through December 31, 2029. It preserved liability protections for manufacturers, distributors, program planners, pharmacists, pharmacy technicians, and other qualified persons involved in covered Covid countermeasures.

That is why the new contracts matter so much.

The government is not merely buying a product. It is buying that product inside a special legal structure that limits ordinary routes of accountability for injuries caused by it.

Kennedy has had time and authority to end that injustice. He knows exactly what it is. In 2023, he described the PREP Act as a shield that allows pharmaceutical companies “to get away with mass murder.”

And yet, now in power, Kennedy has failed to act.

The episode is another reminder that the federal government has no constitutional authority to manage healthcare. As this magazine has long argued, that power must be returned to the states, local communities, and families forced to live with the consequences.

from:    https://thenewamerican.com/us/healthcare/cdc-awards-pfizer-1-24-billion-for-updated-covid-vaccines/

Saving the Food Supply

Leaked draft of the MAHA Commission Report Leaves Much to Be Desired/ Farm Action

FOR IMMEDIATE RELEASE

https://farmaction.us/leaked-maha-strategy-falls-short-earns-d-from-farm-action/
August 18, 2025

Media Contact: Jessica Cusworth, 202-450-0887, jcusworth@farmaction.us

Leaked MAHA Strategy Falls Short, Earns D+ from Farm Action

Washington, D.C. — Angela Huffman, President of Farm Action, issued the following statement in response to the leaked draft of the Make America Healthy Again strategy report:

The leaked draft of the Make America Healthy Again strategy earns a D+ from Farm Action. It recognizes some of the right priorities and even overlaps with our recommendations in places, but the execution is timid and avoids the structural reforms needed to truly deliver on the MAHA Commission’s own diagnosis of the problem.

The Commission’s April assessment called out systemic issues like corporate capture and consolidation in the food system, chemical contamination in agriculture, and federal programs like crop insurance that drive production of commodity crops over healthy foods.

But between April and August, the White House met with powerful lobbyists, and the influence shows. The draft avoids antitrust action on monopoly power in food production, processing, and retail. While it nods to soil health, it punts on pesticide dependence—offering only “precision application” and reassurances to lobbyists instead of a real transition plan. It also leaves crop insurance and subsidy distortions untouched, keeping fruit and vegetable growers at a disadvantage. Overall, it’s a far cry from the bold promises of structural reform made on the campaign trail.

The draft is not without positives, like easing barriers for CSAs and direct-to-consumer sales, improving farm-to-school grants, supporting small meat processors and mobile units, and expanding voluntary soil health programs—the kind of steps Farm Action recommended to the Commission. But these scattered measures are thin on detail and overshadowed by the reluctance to take on reforms at the scale of the problem.

We’ll be watching for the final version from the White House. As the only farm group to have publicly endorsed RFK Jr. for HHS Secretary, we expect the final strategy to deliver on the promises made to farmers and rural America.

###

Farm Action is a nonpartisan agricultural watchdog organization led by farmers. We advocate for accountability from both our government and large corporations within the agricultural sector. We envision a fair, sustainable, and healthy food system that empowers farmers, workers, and rural communities to feed America.

from:    https://merylnass.substack.com/p/leaked-draft-of-the-maha-commission?publication_id=746368&post_id=171281154&isFreemail=true&r=19iztd&triedRedirect=true&utm_source=substack&utm_medium=email